ライフサイエンスコーパス: adverse events related to

1 Adverse events related to injection site were more common in

2 Adverse events related to photochemical internalisation were

3 Adverse events related to study drug were less common with bi

4 Grade 3-4 adverse events related to nivolumab included increased lipase

5 the data and safety monitoring committee [DSMC]) grade 3-4 adverse events related to the vaccine (judged by the DSMC) wi

6 Four (4%) patients presented grade 3 or 4 adverse events related to TG4010 and other study treatments (

7 All adverse events related to the medication were recorded.

8 Quality of life is also improved, although adverse events related to device therapy remain common.

9 Thirteen patients (52%) experienced adverse events related to extracorporeal CO2 removal.

10 %], respectively, had at least one adverse event), with few adverse events related to renal function (1% vs <1%) or volum

11 Modest adverse events related to Opra Kappa included pruritus, obser

12 No adverse events related to the AAV were reported, and those re

13 No adverse events related to the intervention were detected, but

14 No adverse events related to the intervention were reported.

15 UC-MSC-treated patients presented no adverse events related to the cell infusion, and none of the

16 There were no adverse events related to ridinilazole that led to discontinu

17 The most common ocular adverse events related to pazopanib and ranibizumab were appl

18 Patients on ADT+RT reported a higher frequency of adverse events related to bowel toxicity, but only two of 589

19 s needed to properly describe the incidence and severity of adverse events related to probiotics.

20 Only adverse events related to device use were collected; 54 adver

21 No complications or adverse events related to contrast-enhanced US occurred.

22 ts receiving acetylcysteine vs 50 [81%] receiving placebo), adverse events related to study treatment (17 [28%] vs 16 [26

23 Investigators did not report adverse events related to E10030 or ranibizumab.

24 Serious adverse events related to treatment, including four versus on

25 Serious adverse events related to vaccination occurred in five (0.2%)

26 II-IV acute GVHD, non-relapse mortality by day 100, serious adverse events related to the vaccine (judged by the data and

27 19 serious adverse events related to pictilisib treatment were reported

28 Fistula repair was not associated with any serious adverse events related to mesenchymal stem cells or plug plac

29 The most common serious adverse events related to study treatment were pyrexia for da

30 lled period: one event of aplastic anaemia and five serious adverse events related to raised concentrations of eosinophil

31 Four serious adverse events related to pictilisib treatment were reported

32 he primary safety endpoint of 12-month freedom from serious adverse events related to the procedure, system, or therapy w

33 missions, but patients in the repair group had more serious adverse events related to heart failure (P=0.05) and cardiova

34 No serious adverse events related to botulinum toxin use were observed.

35 ajority of adverse events were mild in severity; no serious adverse events related to study drug and no relevant laborato

36 No serious adverse events related to tenofovir use were reported.

37 specific antibody to rh-FGF-2 were detected, and no serious adverse events related to the products were reported.

38 There were no serious adverse events related to the study drug.

39 ix mild local reactions occurred, and there were no serious adverse events related to the study medication.

40 No serious adverse events related to treatment were reported in the tria

41 he simvastatin group (P = .752); the percentages of serious adverse events related to therapy were 11% in the placebo gro

42 No suspected unexpected serious adverse reactions or severe adverse events related to vaccination were reported.

43 e events were frequent, but there were no serious or severe adverse events related to vaccination.

44 As in adults, no serious or severe adverse events related to vaccine occurred in adolescents or

45 as well tolerated, and there were no clinically significant adverse events related to AAV2-neurturin.

46 There were no significant adverse events related to the procedure.

47 st is helpful for the monitoring and management of systemic adverse events related to patient systemic immunosuppression.

48 nt visits in the United States every year are attributed to adverse events related to dietary supplements.

49 98) emergency department visits per year were attributed to adverse events related to dietary supplements.

50 Two adverse events related to HIV self-testing were reported: int